Krystal Biotech (MIL:1KRYS) Cyclically Adjusted PB Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIL:1KRYS Krystal Biotech Inc MIL:1KRYS
40 GF Score
Price €302.30
GF Value €298.92
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Krystal Biotech Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Krystal Biotech  (MIL:1KRYS) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Krystal Biotech Cyclically Adjusted PB Ratio Related Terms


Krystal Biotech Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Krystal Biotech's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Krystal Biotech Cyclically Adjusted PB Ratio Chart

Krystal Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 11.68

Krystal Biotech Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 11.93 11.95 17.00

MIL:1KRYS vs AXSM, APGE, IONS: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Krystal Biotech's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Krystal Biotech Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Krystal Biotech's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Krystal Biotech's Cyclically Adjusted PB Ratio falls into.


MIL:1KRYS
40GF Score
Krystal Biotech Inc MIL:1KRYS
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Krystal Biotech Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Krystal Biotech's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Krystal Biotech's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=40.167/333.9520*333.9520
=40.167

Current CPI (Jun. 2026) = 333.9520.

Krystal Biotech Quarterly Data

Book Value per Share CPI Adj_Book
201609 241.428 0.000
201612 -0.103 241.432 -0.142
201703 -0.139 243.801 -0.190
201706 -0.191 244.955 -0.260
201709 4.148 246.819 5.612
201712 3.997 246.524 5.415
201803 3.738 249.554 5.002
201806 3.745 251.989 4.963
201809 4.101 252.439 5.425
201812 6.865 251.233 9.125
201903 6.751 254.202 8.869
201906 10.276 256.143 13.398
201909 11.005 256.759 14.314
201912 10.416 256.974 13.536
202003 10.408 258.115 13.466
202006 14.022 257.797 18.164
202009 13.056 260.280 16.751
202012 12.109 260.474 15.525
202103 16.502 264.877 20.805
202106 15.894 271.696 19.536
202109 15.840 274.310 19.284
202112 20.706 278.802 24.802
202203 19.565 287.504 22.726
202206 20.841 296.311 23.488
202209 21.471 296.808 24.158
202212 18.993 296.797 21.371
202303 17.468 301.836 19.327
202306 21.399 305.109 23.422
202309 25.324 307.789 27.477
202312 24.963 306.746 27.177
202403 25.941 312.332 27.737
202406 27.264 314.175 28.980
202409 27.601 315.301 29.234
202412 31.740 315.605 33.585
202503 31.543 319.799 32.939
202506 30.647 322.561 31.729
202509 33.412 324.800 34.353
202512 35.572 324.054 36.659
202603 37.642 330.213 38.068
202606 40.167 333.952 40.167

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Krystal Biotech (MIL:1KRYS) Overvalued in 2026?

Based on GuruFocus' analysis, Krystal Biotech stock appears to be overvalued. The current stock price of €302.30 is trading 1.1% above its estimated GF Value™ of €298.92. GuruFocus considers Krystal Biotech to be Fairly Valued.

Key valuation signals for MIL:1KRYS:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €298.92 vs. price of €302.30 (1.1% above fair value)
  • GF Score™: 40/100 with 3 warning signs

No single metric tells the full story. See the MIL:1KRYS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Krystal Biotech Business Description

Other Exchanges KRYS:USA4KB:Germany
Address 2100 Wharton Street, Suite 701, Pittsburgh, PA, USA, 15203
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
40GF Score

Get the complete analysis for MIL:1KRYS

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€302.30
Price
€298.92
GF Value